Kenvue’s 458th-Ranked Volume and 0.88% Drop as Sender Co Digs to 3.8% Stake Amid Strategic Shifts and Leadership Changes

Kenvue (KVUE) fell 0.88% on August 21, with a trading volume of $0.19 billion, ranking 458th in market activity. Sender Co & Partners, Inc. increased its stake in the consumer health company by 530,717 shares, valued at $12.08 million, making Kenvue its largest disclosed position at 3.8% of reported equity AUM as of Q2 2025. The move reflects investor interest in Kenvue’s potential turnaround following strategic shifts and board changes.

The investment firm now holds 645,397 shares, valued at $13.5 million, as Kenvue trades at $21.10—16.2% below its 52-week high. Despite a 3.9% dividend yield, the stock has underperformed the S&P 500 by 17.5 percentage points over the past year. Activist investor Starboard Value’s March agreement to appoint three board members, including its CEO, has influenced investor sentiment, though the July removal of CEO Thibault Mongon triggered an ongoing strategic review and search for a permanent replacement.

Analysts suggest the stock’s appeal lies in its portfolio of established brands like Tylenol and Neutrogena, but challenges remain in closing gaps with peers, particularly in the skin health and beauty segment. The board’s ability to execute operational improvements and stabilize leadership will be critical for Kenvue’s long-term performance in a competitive consumer health market.

The strategy of buying the top 500 stocks by daily trading volume and holding them for one day from 2022 to now delivered moderate returns. The 1-day return was 1.98%, with a total return of 7.61% over 365 days. The strategy's Sharpe ratio was 0.94, indicating good risk-adjusted returns. However, the maximum drawdown of -29.16% highlights its vulnerability during market downturns.